Atherogenic index of plasma (AIP) may be a robust biomarker for cardiovascular diseases (CVDs), according to a study published in Cardiovascular Diabetology.

In this secondary analysis of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, researchers analyzed 10,251 patients with long-lasting T2DM. They used receiver operating characteristic curve analysis was used to discern an optimal threshold for AIP, while the population of interest was divided into high and low AIP groups.

The primary endpoints were defined as major adverse cardiovascular events (MACEs), including nonfatal myocardial infarction, nonfatal stroke, and/or death from cardiovascular causes, and while the secondary outcome was all-cause mortality. The endpoints were assessed using univariable and multivariable Cox proportional hazards regression.

Following analysis, the results showed that multivariable analysis showed that AIP was associated with the risk of MACEs, all-cause mortality, cardiovascular death, and nonfatal myocardial infarction. Subgroup stratified analyses showed that AIP might interact with sex, a classical risk factor of cardiovascular events.

“This study showed that AIP might be a strong biomarker that could be used to predict the risk of cardiovascular events in patients with T2DM,” the researchers concluded.

Keywords: Atherogenic index of plasma, Atherosclerosis, Cardiovascular disease, Major adverse cardiovascular events, Prognosis, Type 2 diabetes mellitus